Previous 10 | Next 10 |
home / stock / gcvrz / gcvrz news
2023-10-19 09:58:30 ET More on Sanofi, GoodRx, etc. GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In GoodRx Stock: Earnings Momentum Keeps It Interesting Sanofi: 3 Reasons For A Buy Sanofi presents encouraging data on at...
2023-10-04 06:31:10 ET More on Teva Teva considering potential sale of inflammatory bowel disease asset - Bloomberg Teva: Focus On Innovation And Growth Means The Times They Are A Changing The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider...
2023-09-26 07:49:48 ET More on Regeneron Seeking Alpha’s Quant Rating on Regeneron Pharmaceuticals Financial information for Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron Gets Boost With FDA Appr...
2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...
2023-09-17 12:00:54 ET The impact of COVID, flu, and RSV on U.S. and U.K. hospitals is expected to be lower this winter compared to last, as there won't be a significant overlap between peak outbreaks of infections, the London-based data analytics firm Airfinity said in a recent report. ...
2023-09-14 06:46:02 ET More on Sanofi Sanofi: A 'Buy' Recommendation For Undervalued Growth Potential Sanofi ( SNY ) Q2 2023 Earnings Call Transcript Sanofi 2023 Q2 - Results - Earnings Call Presentation Sanofi: Powering Up And Offering Investors A Lot Of...
2023-07-28 02:01:29 ET Sanofi press release ( NASDAQ: SNY ): Q2 Non-GAAP EPS of €1.74. Revenue of €9.96B (-2.1% Y/Y), sales growth of 3.3% at CER. Specialty Care grew 11.8% driven by Dupixent ® (€2,562 million, +34.2%) and Nexvia...
2023-06-01 11:28:37 ET Summary Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces significant challenges in marketing Inpefa against ...
2023-05-25 19:36:30 ET Summary It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche Holding AG reported positive results reported from ...
2023-04-23 20:50:13 ET Healthcare giant Johnson & Johnson ( NYSE: JNJ ) is expected to begin a roadshow to pitch shares of its consumer-healthcare spinoff, Kenvue, as early as Monday, The Wall Street Journal reported citing people familiar with the matter. Kenvue plans t...
News, Short Squeeze, Breakout and More Instantly...
Sanofi Contingent Value Right (Expiring 12/31/2020) Company Name:
GCVRZ Stock Symbol:
NASDAQ Market:
Sanofi Contingent Value Right (Expiring 12/31/2020) Website:
* The British Pharmacological Society awards Cablivi® (caplacizumab), the first new treatment in 30 years for acquired Thrombotic Thrombocytopenic Purpura (aTTP), Drug Discovery of the Year 2020 * TTP is a rare blood clotting disorder with 330 people known to be affected i...